BCMA-CD19 compound CAR (cCAR) T cells vs ICG318

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Systemic Lupus Erythematosus

Shared mechanism: BCMA / CD19 · full Systemic Lupus Erythematosus pipeline

BCMA-CD19 compound CAR (cCAR) T cells

Developed by iCell Gene Therapeutics

Phase 1 in Systemic Lupus ErythematosusCAR-T cell therapy (dual-target)
Weak signal

NCT05474885 · Phase 1 · status unknown

This was a small, single-arm, open-label Phase 1 study in patients with relapsed or refractory lupus, with no control group and no blinding. Early results describe a favorable safety profile with only mild cytokine release syndrome, and improvements in autoantibody levels and disease activity, but the uncontrolled design means these findings cannot show how much of the improvement is due to the treatment itself.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

The number and incidence of adverse events after BCMA-CD19 cCAR T cell infusion (3 months after CAR infusion): All patients (12/13) who received an initial dose of 3x10^6 cCAR cells/kg were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR. Therapy was well tolerated with mild cytokine-release syndrome (no CRS above grade 1), and mean SLE Disease Activity Index 2000 (SLEDAI-2K) fell from 9.9 at baseline to 2.3 at 3 months. (not_applicable)

Result source: NCT05474885

ICG318

Developed by iCell Gene Therapeutics

Phase 2 in Systemic Lupus ErythematosusCell therapy (BCMA-CD19 armored compound CAR-T)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2028 · NCT07328581 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Systemic Lupus Erythematosus

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBCMA-CD19 compound CAR (cCAR) T cellsICG318
SRI-4—Not reported—Not reported
BICLA—Not reported—Not reported
CLASI-50—Not reported—Not reported
Steroid sparing—Not reported—Not reported

SRI-4

BCMA-CD19 compound CAR (cCAR) T cells
—Not reported
ICG318
—Not reported

BICLA

BCMA-CD19 compound CAR (cCAR) T cells
—Not reported
ICG318
—Not reported

CLASI-50

BCMA-CD19 compound CAR (cCAR) T cells
—Not reported
ICG318
—Not reported

Steroid sparing

BCMA-CD19 compound CAR (cCAR) T cells
—Not reported
ICG318
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ICG318: no structured comparison results are available for Systemic Lupus Erythematosus.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

BCMA-CD19 compound CAR (cCAR) T cells
All patients (12/13) who received an initial dose of 3x10^6 cCAR cells/kg were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR. Therapy was well tolerated with mild cytokine-release syndrome (no CRS above grade 1), and mean SLE Disease Activity Index 2000 (SLEDAI-2K) fell from 9.9 at baseline to 2.3 at 3 months. NCT05474885 · Phase 1 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA-CD19 compound CAR (cCAR) T cells's landscape · ICG318's landscape